keyword
https://read.qxmd.com/read/38071825/favorable-combinations-of-antiseizure-medication-with-vagus-nerve-stimulation-to-improve-health-related-quality-of-life-in-patients-with-epilepsy
#21
JOURNAL ARTICLE
Victoria Sauer, Martin Glaser, Erik Ellwardt, Assel Saryyeva, Joachim K Krauss, Florian Ringel, Sergiu Groppa, Yaroslav Winter
BACKGROUND: Vagus nerve stimulation (VNS) is a non-pharmacological treatment of refractory epilepsy, which also has an antidepressive effect. The favorable combinations of VNS with specific mechanisms of action of antiseizure medication (ASM) on mood and health-related quality of life (HrQol) have not yet been studied. The objective was to identify favourable combinations of specific ASMs with VNS for the HrQoL and depression in refractory epilepsy. METHODS: We performed an observational study including patients with refractory epilepsy and an implanted VNS (N = 151)...
December 9, 2023: Epilepsy & Behavior: E&B
https://read.qxmd.com/read/38070405/brivaracetam-as-add-on-therapy-in-children-with-developmental-epileptic-encephalopathies-a-study-of-42-patients
#22
JOURNAL ARTICLE
Roberto H Caraballo, Gabriela Reyes, Santiago Chacón, Pablo Sebastián Fortini
OBJECTIVE: Here we present a multicenter series of patients with developmental epileptic encephalopathies (DEE) who were treated with brivaracetam (BRV) as add-on therapy. METHODS: Medical records of 42 patients with DEE treated with add-on BRV seen at four pediatric neurology centers in Argentina between January 2021 and July 2023 were retrospectively analyzed. RESULTS: We included 42 patients (26 males, 16 females) with a mean age of 7 years (SD, ± 3...
December 8, 2023: Epilepsy & Behavior: E&B
https://read.qxmd.com/read/38061273/predictors-of-clinically-significant-anhedonia-in-refractory-epilepsy
#23
JOURNAL ARTICLE
Surapi Wijayendran, Rofael Jabr, Lucy Roberts-West, Dorothea Bindman, Matthew C Walker, Sallie Baxendale, Umesh Vivekananda
BACKGROUND: Anhedonia, the inability to feel pleasure or motivation for reward, is a core feature of depression in epilepsy, but can occur independent from depression. It is reported in over a third of people with epilepsy and has a significant impact on quality of life. OBJECTIVES: This study determined whether specific features of medication refractory epilepsy are predictive of anhedonia. DESIGN: We assessed 267 patients with medication refractory epilepsy for anhedonia, primarily using the clinically validated Snaith-Hamilton Pleasure Scale (SHAPS) scale...
December 2, 2023: Journal of the Neurological Sciences
https://read.qxmd.com/read/38052481/a-real-world-comparison-among-third-generation-antiseizure-medications-results-from-the-compare-study
#24
JOURNAL ARTICLE
Roberta Roberti, Gianfranco Di Gennaro, Francesca Anzellotti, Dario Arnaldi, Vincenzo Belcastro, Simone Beretta, Giovanni Boero, Paolo Bonanni, Laura Canafoglia, Alfredo D'Aniello, Filippo Dainese, Carmen De Caro, Giancarlo Di Gennaro, Roberta Di Giacomo, Jacopo C DiFrancesco, Fedele Dono, Giovanni Falcicchio, Edoardo Ferlazzo, Nicoletta Foschi, Silvia Franciotta, Antonio Gambardella, Alfonso Giordano, Luigi Francesco Iannone, Angelo Labate, Angela La Neve, Simona Lattanzi, Ugo Leggio, Claudio Liguori, Marta Maschio, Annacarmen Nilo, Francesca Felicia Operto, Angelo Pascarella, Giada Pauletto, Rosaria Renna, Gionata Strigaro, Emilio Russo
OBJECTIVE: There is little comparative data on the third-generation antiseizure medications (ASMs). We aimed to assess and compare the effectiveness of brivaracetam (BRV), eslicarbazepine acetate (ESL), lacosamide (LCM) and perampanel (PER) in people with epilepsy (PWE). Efficacy and tolerability were compared as secondary objectives. METHODS: A multicenter, retrospective study collecting data from 22 Italian neurology/epilepsy centres. All adult PWE who started add-on treatment with one of the studied ASMs between January 2018 and October 2021 were included...
December 5, 2023: Epilepsia
https://read.qxmd.com/read/38049197/pharmacokinetics-and-safety-of-brivaracetam-in-neonates-with-repeated-electroencephalographic-seizures-a-multicenter-open-label-single-arm-study
#25
JOURNAL ARTICLE
Ronit Pressler, Geraldine Boylan, Eugene Dempsey, Kerstin Alexandra Klotz, Walter Krauwinkel, Edgar Will, Diego Morita, Florin Floricel, Jan-Peer Elshoff, John van den Anker
OBJECTIVE: To evaluate the pharmacokinetics (PK), safety and tolerability of brivaracetam (BRV) in neonates with repeated electroencephalographic seizures not controlled with previous antiseizure medications (ASMs). METHODS: Phase 2/3, multicenter, open-label, single-arm study (N01349/NCT03325439) in neonates with repeated electroencephalographic seizures (lasting ≥10 seconds) confirmed by video-electroencephalography, and inadequate seizure control with ≥1 ASMs...
December 4, 2023: Epilepsia Open
https://read.qxmd.com/read/38029647/normalization-and-cross-sectional-validation-of-an-extended-adverse-event-profile-e-aep-in-a-large-cohort-of-patients-with-epilepsy
#26
JOURNAL ARTICLE
Christoph Helmstaedter, Carolin Meschede, Sandra Mastani, Susanna Moskau-Hartmann, Michael Rademacher, Randi von Wrede, Juri-Alexander Witt
PURPOSE: The Liverpool Adverse Event Profile (L AEP) is commonly used in clinical practice and pharmacological trials for the monitoring of side effects of anti-seizure medication (ASM). However potentially unrelated, additional symptoms and normative data should be considered to put patients´ complaints into perspective. METHODS: An extended 32-item AEP (E AEP) was given to 537 healthy subjects and 1,605 patients with epilepsy as part of the Bonn ASM side effect registry...
January 2024: Seizure: the Journal of the British Epilepsy Association
https://read.qxmd.com/read/37928141/vagus-nerve-stimulation-for-treating-developmental-and-epileptic-encephalopathy-in-young-children
#27
JOURNAL ARTICLE
Guifu Geng, Wandong Hu, Yao Meng, Huan Zhang, Hongwei Zhang, Chuanmei Chen, Yanqing Zhang, Zaifen Gao, Yong Liu, Jianguo Shi
OBJECTIVE: To investigate the clinical variables that might predict the outcome of developmental and epileptic encephalopathy (DEE) after vagus nerve stimulation (VNS) therapy and identify the risk factors for poor long-term outcome. PATIENTS AND METHODS: We retrospectively studied 32 consecutive children with drug-resistant DEE who had undergone VNS surgery from April 2019 to July 2021, which were not suitable for corpus callosotomy. In spite of combining valproic acid, levetiracetam, lamotrigine, topiramate, etc...
2023: Frontiers in Neurology
https://read.qxmd.com/read/37897555/development-of-sv2a-ligands-for-epilepsy-treatment-a-review-of-levetiracetam-brivaracetam-and-padsevonil
#28
REVIEW
Peng-Peng Wu, Bi-Rong Cao, Fu-Yun Tian, Zhao-Bing Gao
Epilepsy is a common neurological disorder that is primarily treated with antiseizure medications (ASMs). Although dozens of ASMs are available in the clinic, approximately 30% of epileptic patients have medically refractory seizures; other limitations in most traditional ASMs include poor tolerability and drug-drug interactions. Therefore, there is an urgent need to develop alternative ASMs. Levetiracetam (LEV) is a first-line ASM that is well tolerated, has promising efficacy, and has little drug-drug interaction...
October 28, 2023: Neuroscience Bulletin
https://read.qxmd.com/read/37857032/real-world-practices-for-the-care-of-women-with-epilepsy-during-pregnancy-a-canadian-perspective
#29
JOURNAL ARTICLE
Tadeu A Fantaneanu, Hayley F Thornton, Tinghua Zhang, Eduard Bercovici, Chantelle Hrazdil, Kristin M Ikeda, Janani Kassiri, Ana Suller Marti, Raluca Pana, Arezoo Rezazadeh, Eliane Kobayashi, Esther Bui
OBJECTIVE: Approximately 150,000 Canadian women live with epilepsy, a population that presents with unique challenges. Our objective was to capture demographic and real-world practice characteristics of Canadian healthcare professionals providing care for women with epilepsy (WWE) with specific focus on reproductive considerations to identify potential gaps in knowledge and care. METHODS: A questionnaire developed by the Canadian League Against Epilepsy WWE workgroup was distributed to Canadian healthcare professionals from February 2021 to October 2022 to capture participant demographic characteristics and practice patterns in key areas of the reproductive cycle in WWE...
October 17, 2023: Epilepsy & Behavior: E&B
https://read.qxmd.com/read/37839249/the-real-world-effectiveness-of-intravenous-brivaracetam-as-a-second-line-treatment-in-status-epilepticus
#30
JOURNAL ARTICLE
Chiara Martellino, Angelina Laganà, Giorgia Atanasio, Fabio Lamanna, Silvia Attardo, Simona Cascino, Marcella De Luca, Orazio Pardeo, Giuseppa Giacobbe, Giovanni Tripepi, Roberta Roberti, Francesca Granata, Carmela Morace, Emilio Russo, Angelo Labate
PURPOSE: Status epilepticus (SE) is defined by abnormally prolonged seizures that may lead to brain damage and death. Our aim was to evaluate the efficacy and tolerability (effectiveness) of intravenous brivaracetam (BRV) as a second-line treatment. METHODS: Twenty-one patients (median age 68 years ± 17.28) were prospectively recruited between June 2019 and December 2022. Patients were treated with BRV (50-200 mg) as a second-line add-on therapy for SE...
October 13, 2023: Epilepsy & Behavior: E&B
https://read.qxmd.com/read/37784006/third-generation-antiseizure-medication-in-the-treatment-of-benzodiazepine-refractory-status-epilepticus-in-poststroke-epilepsy-a-retrospective-observational-register-based-study
#31
JOURNAL ARTICLE
Yaroslav Winter, Katharina Sandner, Thomas Vieth, Gabriel Gonzalez-Escamilla, Sebastian V Stuckrad-Barre, Sergiu Groppa
BACKGROUND AND OBJECTIVE: Status epilepticus in poststroke epilepsy is a challenging condition because of multiple vascular comorbidities and the advanced age of patients. Data on third-generation antiseizure medication (ASM) in this condition are limited. The aim of this study was to evaluate the efficacy of third-generation ASMs in the second- or third-line therapy of benzodiazepine-refractory status epilepticus in poststroke epilepsy following acute ischemic stroke. METHODS: Data on the effectiveness of third-generation ASMs in patients with status epilepticus in poststroke epilepsy were gathered from two German Stroke Registries and the Mainz Epilepsy Registry...
October 2023: CNS Drugs
https://read.qxmd.com/read/37741165/real-world-analysis-of-retention-on-cenobamate-in-patients-with-epilepsy-in-the-united-states
#32
JOURNAL ARTICLE
Sean Stern, Mindl Weingarten, Sudhakar Mandapati, Louis Ferrari, Clarence T Wade
BACKGROUND: This retrospective, observational study used US claims data to assess retention rates on cenobamate compared with four branded antiseizure medications (ASMs) in patients with epilepsy. METHODS: Adults (≥18 years) with prevalent epilepsy (ICD-10 code G40.xx) and ≥ 1 prescription for cenobamate or any of the newer branded ASMs (brivaracetam, eslicarbazepine, lacosamide, or perampanel) between May 1, 2020 and December 31, 2021 were identified from the HealthVerity Marketplace database...
November 2023: Epilepsy Research
https://read.qxmd.com/read/37684497/effectiveness-and-tolerability-of-12-month-brivaracetam-in-the-real-world-experience-an-international-pooled-analysis-of-individual-patient-records
#33
JOURNAL ARTICLE
Vicente Villanueva, Cédric Laloyaux, Wendyl D'Souza, Edward Faught, Pavel Klein, Markus Reuber, Felix Rosenow, Javier Salas-Puig, Victor Soto Insuga, Adam Strzelczyk, Jerzy P Szaflarski, Chris Chinn, Tony Daniels, Florin Floricel, David Friesen, Veronica Sendersky, Hervé Besson, Bernhard J Steinhoff
BACKGROUND AND OBJECTIVE: Real-world evidence studies of brivaracetam (BRV) have been restricted in scope, location, and patient numbers. The objective of this pooled analysis was to assess effectiveness and tolerability of brivaracetam (BRV) in routine practice in a large international population. METHODS: EXPERIENCE/EPD332 was a pooled analysis of individual patient records from multiple independent non-interventional studies of patients with epilepsy initiating BRV in Australia, Europe, and the United States...
September 9, 2023: CNS Drugs
https://read.qxmd.com/read/37684052/management-of-epilepsy-during-pregnancy-and-lactation
#34
REVIEW
Omotola A Hope, Katherine Mj Harris
Epilepsy is a group of neurological diseases characterized by susceptibility to recurrent seizures. Antiseizure medications (ASMs) are the mainstay of treatment, but many antiseizure medications with variable safety profiles have been approved for use. For women with epilepsy in their childbearing years, the safety profile is important for them and their unborn children, because treatment is often required to protect them from seizures during pregnancy and lactation. Since no large randomized controlled trials have investigated safety in this subgroup of people with epilepsy, pregnancy registries, cohort and case-control studies from population registries, and a few large prospective cohort studies have played an important role...
September 8, 2023: BMJ: British Medical Journal
https://read.qxmd.com/read/37634373/real-life-evidence-about-the-use-of-intravenous-brivaracetam-in-urgent-seizures-the-briv-iv-study
#35
JOURNAL ARTICLE
Vicente Villanueva, Xiana Rodriguez-Osorio, Álvaro Juiz-Fernández, Debora Sayas, Kevin Hampel, Ascensión Castillo, Javier Montoya, Mercedes Garcés, Dulce Campos, Eduardo Rubio-Nazábal, Alejandro Fernández-Cabrera, Ariadna Gifreu, Estevo Santamarina, Guillermo Hernández Pérez, Mercé Falip, Beatriz Parejo-Carbonell, Irene García-Morales, Ana Belen Martínez, Margarita Massot, Montserrat Asensio, Juana Giménez, Virginia Guillén, Jesus Ruiz-Giménez, Beatriz Chavarria, Rodrigo Rocamora, Inés Escalza
PURPOSE: Urgent seizures are a medical emergency for which new therapies are still needed. This study evaluated the use of intravenous brivaracetam (IV-BRV) in an emergency setting in clinical practice. METHODS: BRIV-IV was a retrospective, multicenter, observational study. It included patients ≥18 years old who were diagnosed with urgent seizures (including status epilepticus (SE), acute repetitive seizures, and high-risk seizures) and who were treated with IV-BRV according to clinical practice in 14 hospital centers...
August 25, 2023: Epilepsy & Behavior: E&B
https://read.qxmd.com/read/37626674/modulating-hyperpolarization-activated-cation-currents-through-small-molecule-perturbations-magnitude-and-gating-control
#36
REVIEW
Cheng-Shih Chen, Edmund Cheung So, Sheng-Nan Wu
The hyperpolarization-activated cation current ( I h ) exhibits a slowly activating time course of the current ( I h ) when the cell membrane is hyperpolarized for an extended duration. It is involved in generating electrical activity in various excitable cells. Numerous structurally distinct compounds or herbal drugs have the potential to impact both the magnitude and gating kinetics of this current. Brivaracetam, a chemical analog of levetiracetam known to be a ligand for synaptic vesicle protein 2A, could directly suppress the I h magnitude...
August 2, 2023: Biomedicines
https://read.qxmd.com/read/37619297/4-ap-challenge-reveals-that-early-intervention-with-brivaracetam-prevents-posttraumatic-epileptogenesis-in-rats
#37
JOURNAL ARTICLE
Ana Mejia-Bautista, Hillary B Michelson, Anika Sanjana, Oluwafunmilayo Famuyiwa, Jeffrey H Goodman, Douglas S F Ling
PURPOSE: There are currently no clinical treatments to prevent posttraumatic epilepsy (PTE). Recently, our group has shown that administration of levetiracetam (LEV) or brivaracetam (BRV) shortly after cortical neurotrauma prevents the development of epileptiform activity in rats, as measured ex vivo in neocortical slices. Due to the low incidence of spontaneous seizures in rodent-based models of traumatic brain injury (TBI), chemoconvulsants have been used to test injured animals for seizure susceptibility...
August 19, 2023: Epilepsy Research
https://read.qxmd.com/read/37610448/rapid-switching-from-levetiracetam-to-brivaracetam-in-pharmaco-resistant-epilepsy-in-people-with-and-without-intellectual-disabilities-a-naturalistic-case-control-study
#38
JOURNAL ARTICLE
L V Watkins, H Dunstall, C Musicha, C Lawthom, K John, C Bright, C Richings, K Harding, S Moon, S E Pape, R Winterhalder, V Allgar, R H Thomas, B McLean, R Laugharne, Rohit Shankar
BACKGROUND: Approximately one quarter of people with an intellectual disability (PwID) have epilepsy of whom nearly three-quarters are pharmaco-resistant. There are higher reported neuropsychiatric side-effects to anti-seizure medication (ASM) in this group. Levetiracetam (LEV) is a first-line ASM with a stronger association with neuropsychiatric symptoms for PwID than other ASMs. Brivaracetam (BRV) is a newer ASM. Recent studies suggest a beneficial effect of swapping people who experience neuropsychiatric events with LEV to BRV...
December 2023: Journal of Neurology
https://read.qxmd.com/read/37597326/long-term-safety-and-efficacy-of-adjunctive-brivaracetam-in-pediatric-patients-with-epilepsy-an-open-label-follow-up-trial
#39
JOURNAL ARTICLE
Lieven Lagae, Kerstin Alexandra Klotz, András Fogarasi, Florin Floricel, Christoph Reichel, Jan-Peer Elshoff, Sofia Fleyshman, Harriet Kang
OBJECTIVE: This study was undertaken to evaluate the long-term safety, tolerability, and efficacy of adjunctive brivaracetam (BRV) treatment in pediatric patients with epilepsy. METHODS: A phase 3, open-label, multicenter, long-term follow-up trial (N01266; NCT01364597) was conducted on patients (aged 1 month to <17 years at core trial entry; direct enrollers aged 4 to <17 years) treated with BRV. Outcomes included treatment-emergent adverse events (TEAEs), behavior assessments (Achenbach Child Behavior Checklist [CBCL], Behavior Rating Inventory of Executive Function [BRIEF]/BRIEF-Preschool version [BRIEF-P]), and efficacy outcomes (percent change in focal seizure frequency, 50% responder rate for all seizure types for patient subgroups <2 years and ≥2 years of age using daily record card data)...
August 19, 2023: Epilepsia
https://read.qxmd.com/read/37572859/design-and-evaluation-of-gastro-swelling-gastro-floating-sustained-release-tablets-of-brivaracetam-for-epilepsy-therapy
#40
JOURNAL ARTICLE
Zhiyuan Hou, Xiaoxiao Cheng, Xiangcheng Zhao, Jianing Lin, Hailong Zhang, Youshan Li, Jinsong Ding
To prolong the absorption of the drug and achieve the effect of gastric retention, new brivaracetam tablets together with the characteristics of rapid swelling and sustained floating have been developed here. The tablets were optimized and prepared by direct compression techniques using Kollidon® SR and cross-linked polyvinylpyrrolidone (PVPP) XL as the matrix and disintegrant respectively, and carbomer 71G NF and polyethylene oxide (PEO) N60K as the gel materials to achieve sustained release effect. The characteristics of static expansion, floating time, drug release and dynamic swelling performance in vitro of the tablets were evaluated...
August 10, 2023: International Journal of Pharmaceutics
keyword
keyword
110670
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.